Yoshihiro Saito

Yoshihiro Saito

Auto-generated profile, based on publicly available information

Yoshihiro Saito

Department of Applied Chemistry and Life Sciences Toyohashi University of Technology Toyohashi Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Hypertension
Verified
Journal Article
Open access
PDF file
RSRyohei Shinohara
Ryohei Shinohara
HNHitomi Nakashima
Hitomi Nakashima
TETakuo Emoto
Takuo Emoto
TYTomoya Yamashita
Tomoya Yamashita
YSYoshihiro Saito
Yoshihiro Saito
KHKen-Ichi Hirata
Ken-Ichi Hirata
Background: Abdominal aortic aneurysm (AAA) is a life-threatening cardiovascular disease characterized by dilated abdominal aorta. Immune cells have been shown to contribute to the development of AAA, and that the gut microbiota is associated with numerous diseases, including cardiovascular diseases, by regulating immune systems or metabolic pathways of the host. However, the interaction between the gut microbiota and AAA remains unknown. Methods: Apolipoprotein E–deficient male mice were fed a high-cholesterol diet and divided into three groups: the control group was maintained under normal water (control group), the oral AVNM group was maintained under drinking water supplemented with ampicillin, vancomycin, neomycin, and metronidazole, and the i.p. AVNM group was injected AVNM intraperitoneally. After 1 week of pretreatment with antibiotics, these mice were administrated Ang II via subcutaneous osmotic pumps for 4 weeks and euthanized to evaluate AAA formation. Results: Depletion of gut microbiota by oral AVNM ameliorated the incidence of AAAs (control group: 58.9% versus oral AVNM group: 28.6% versus i.p. AVNM group: 75.0%, P = 0.0005) and prevented death due to ruptured aneurysms (control group: 11% versus oral AVNM group: 0% versus i.p. AVNM group: 15%). Oral AVNM suppressed monocyte storage in the spleen, but not in other organs. Despite possessing a higher level of cholesterol, recruitment of monocytes into the suprarenal aorta was suppressed in the oral AVNM group. In AVNM drinking mice, NOD1 ligand, a kind of PRR ligands, increased the development of AAAs and accumulation of macrophages in the aortae. Conclusions: The gut microbiota plays a critical role in AAA formation. Therefore, regulation of the microbiota or the immune system can be a therapeutic approach for AAA.

1 September 2021 in International Journal of Cardiology
Verified
Journal Article
Closed access
TETakuo Emoto
Takuo Emoto
THTomohiro Hayashi
Tomohiro Hayashi
TTTokiko Tabata
Tokiko Tabata
TYTomoya Yamashita
Tomoya Yamashita
HWHikaru Watanabe
Hikaru Watanabe
KHKen-Ichi Hirata
Ken-Ichi Hirata

22 April 2021 in Toxins
Verified
Journal Article
Open access
PDF file
TYTomoya Yamashita
Tomoya Yamashita
NYNAOFUMI YOSHIDA
NAOFUMI YOSHIDA
TETakuo Emoto
Takuo Emoto
YSYoshihiro Saito
Yoshihiro Saito
KHKen-Ichi Hirata
Ken-Ichi Hirata
Cardiovascular diseases (CVDs) have become a major health problem because of the associated high morbidity and mortality rates observed in affected patients. Gut microbiota has recently been implicated as a novel endocrine organ that plays critical roles in the regulation of cardiometabolic and renal functions of the host via the production of bioactive metabolites. This review investigated the evidence from several clinical and experimental studies that indicated an association between the gut microbiota-derived toxins and CVDs. We mainly focused on the pro-inflammatory gut microbiota-derived toxins, namely lipopolysaccharides, derived from Gram-negative bacteria, and trimethylamine N-oxide and described the present status of research in association with these toxins, including our previous research findings. Several clinical studies aimed at exploring the effectiveness of reducing the levels of these toxins to inhibit cardiovascular events are currently under investigation or in the planning stages. We believe that some of the methods discussed in this review to eliminate or reduce the levels of such toxins in the body could be clinically applied to prevent CVDs in the near future.

22 August 2009 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
HTHiroyuki Takei
Hiroyuki Takei
MKMasafumi Kurosumi
Masafumi Kurosumi
TYTakashi Yoshida
Takashi Yoshida
YIYuko Ishikawa
Yuko Ishikawa
YHYuji Hayashi
Yuji Hayashi
TTToshio Tabei
Toshio Tabei

1 January 1999 in Journal of the Japan Institute of Metals and Materials
Verified
Journal Article
Open access
PDF file
YSYoshihiro Saito
Yoshihiro Saito
HUHiroshi Utsunomiya
Hiroshi Utsunomiya
Nobuhiro TsujiNobuhiro Tsuji
Nobuhiro Tsuji
TSTetsuo Sakai
Tetsuo Sakai
RHRen-Guo Hong
Ren-Guo Hong
。0勿魏。η(ゾル臨θ磁Zs Sc蜘。6伽4 Eπg勿θθ7勿8;G勉伽碗S6加01σ 伽g痂667勿8;03盈α翫勿θ欝吻, S%吻565-0871 It is known that an ultra-fine grain size can be achieved by a special intense plastic straining processes. In this paper, the authors propose a novel intense plastic straining process named the Accumulative Ro11-Bonding(ARB) for bulk materials. In the process, a strip is put on another strip neatly, at first. The two layered materials are joined together by ro11ing in the manner of a conventional ro11-bonding process。 Then, the length of rolled material

1 January 2015 in Nippon Jibiinkoka Gakkai Kaiho
Verified
Journal Article
Open access
PDF file
TFTaro Fujikawa
Taro Fujikawa
SSSatoru Shirakura
Satoru Shirakura
AHAkio Hatanaka
Akio Hatanaka
WOWataru Okano
Wataru Okano
TTTakao Tokumaru
Takao Tokumaru
TBTakeshi Beppu
Takeshi Beppu
癌治療において低ナトリウム血症はしばしば遭遇する電解質異常である. 今回われわれは, 中咽頭癌進行症例に対してシスプラチン (CDDP) 同時併用放射線治療を行い, 計3回の grade 4 の低ナトリウム血症を経験したので報告する. 初回および2回目の低ナトリウム血症は CDDP 投与後に出現し, 脱水と多尿を伴い, 輸液と塩分の補充により1週間程度で改善した. ナトリウムの排泄過剰の所見から塩類喪失性腎症が原因であると考えられた. 3回目の低ナトリウム血症の原因であった抗利尿ホルモン不適合分泌との比較から, 細胞外液量とナトリウムバランスの評価が低ナトリウム血症の鑑別と適切な治療において極めて重要であると考えられた.